Intellia Therapeutics selects Dr. John Leonard as new CEO

Intellia Therapeutics, a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology, promoted John Leonard, MD, to president and CEO, effective Jan. 1, 2018.

Dr. Leonard, who has worked at Intellia since 2014, currently serves as the company's executive vice president of research and development. He previously served as Intellia's CMO.

Dr. Leonard came to Intellia from AbbVie, a global biopharmaceutical company, where he was chief scientific officer and senior vice president of research and development.

Dr. Leonard succeeds Nessan Bermingham, PhD, Intellia's founding president and CEO, who is leaving for the venture capital arena.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars